Pathways

Betazole, also known as ametazole and Histalog, is a histamine H2 agonist that causes an increase in gastric acid secretion. Betazole is commonly used to evaluate acid production. Betazole binds to the H2 receptor to enhance the G protein signaling cascade to increase gastric secretion into the lumen. Gastric acid digests protein and absorbs calcium, iron and vitamin B12. Gastric acidity may also interfere with medication bioavailability. Measuring gastric acid secretion is useful to manage diseases involving acid production such as gastroesophageal reflux disease.

Betaxolol is a competitive cardioselective beta 1 blocker. It can be administered orally, where it passes through hepatic portal circulation, and enters the bloodstream and travels to act on cardiomyocytes. In bronchial and vascular smooth muscle, betaxolol can compete with epinephrine for beta-2 adrenergic receptors. By competing with catecholamines for adrenergic receptors, it inhibits sympathetic stimulation of the heart. The reduction of neurotransmitters binding to beta receptor proteins in the heart inhibits adenylate cyclase type 1. Because adenylate cyclase type 1 typically activates cAMP synthesis, which in turn activates PKA production, which then activates SRC and nitric oxide synthase, its inhibition causes the inhibition of cAMP, PKA, SRC and nitric oxide synthase signaling. Following this chain of reactions, we see that the inhibition of nitric oxide synthase reduces nitric oxide production outside the cell which results in vasoconstriction. On a different end of this reaction chain, the inhibition of SRC in essence causes the activation of Caspase 3 and Caspase 9. This Caspase cascade leads to cell apoptosis. The net result of all these reactions is a decreased sympathetic effect on cardiac cells, causing the heart rate to slow and arterial blood pressure to lower; thus, betaxolol administration and binding reduces resting heart rate, cardiac output, afterload, blood pressure and orthostatic hypotension. By prolonging diastolic time, it can prevent re-infarction. Clinically, it is used to increase atrioventricular block to treat supraventricular dysrhythmias. Betaxolol also reduce sympathetic activity and is used to treat hypertension, angina, migraine headaches, and hypertrophic subaortic stenosis.

Betaxolol is a competitive cardioselective beta 1 blocker. It can be administered orally, where it passes through hepatic portal circulation, and enters the bloodstream and travels to act on cardiomyocytes. In bronchial and vascular smooth muscle, betaxolol can compete with epinephrine for beta adrenergic receptors. By competing with catecholamines for adrenergic receptors, it inhibits sympathetic stimulation of the heart. The reduction of neurotransmitters binding to beta receptor proteins in the heart inhibits adenylate cyclase type 1. Because adenylate cyclase type 1 typically activates cAMP synthesis, which in turn activates PKA production, which then activates SRC and nitric oxide synthase, its inhibition causes the inhibition of cAMP, PKA, SRC and nitric oxide synthase signaling. Following this chain of reactions, we see that the inhibition of nitric oxide synthase reduces nitric oxide production outside the cell which results in vasoconstriction. On a different end of this reaction chain, the inhibition of SRC in essence causes the activation of Caspase 3 and Caspase 9. This Caspase cascade leads to cell apoptosis. The net result of all these reactions is a decreased sympathetic effect on cardiac cells, causing the heart rate to slow and arterial blood pressure to lower; thus, betaxolol administration and binding reduces resting heart rate, cardiac output, afterload, blood pressure and orthostatic hypotension. By prolonging diastolic time, it can prevent re-infarction. Clinically, it is used to increase atrioventricular block to treat supraventricular dysrhythmias. Betaxolol also reduce sympathetic activity and is used to treat hypertension, angina, migraine headaches, and hypertrophic subaortic stenosis. Some side effects of using betaxolol may include tiredness, heartburn, nausea, and joint pain.

Betaxolol (also known as Betoptic or Lokren) is a selective beta blocker that can block beta1-adrenergic receptors and beta2-adrenergic receptors. Blocking of beta1-adrenergic receptors in heart and vascular smooth muscle can lead to reduced heart rate, cardiac output, and decreased blood pressure. Blocking of beta(2)-adrenergic receptors can lead to prevention of bronchospasm.

Metabolites of Betamethasone phosphate are predicted with biotransformer.

Betamethasone phosphate is a prodrug that is rapidly metabolized to betamethasone. It is used to treat many inflammatory conditions like allergic states, dermatologic diseases, hematologic disorders, renal diseases, respiratory diseases, rheumatic disorders, and endocrine disorders. This drug is indicated when oral therapy is not feasible, it is an injectable suspension usually used intramuscularly, intralesionally, or by the intra-articular route. As betamethasone is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) of influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Betamethasone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation.

Betamethasone is a long-acting and systemic corticosteroid used to relieve inflammation in various conditions, including allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders. It is available as a cream/ointment but also as an injectable solution. Corticosteroids bind to the glucocorticoid receptor to promote anti-inflammatory signals. As betamethasone is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) of influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Betamethasone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation. Betamethasone is administered in many different routes; eye drops, oral tablets, rectal enema, topical cream, and many others.